http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2016348180-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_709b4a26ef028713f9b302509eb824d7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f7622b803d44677534e05057ccd58cd7
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-136
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-243
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-24
classificationIPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-336
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-243
filingDate 2016-02-24-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_72f4565b6bda738696aa8e0d9dcf13fb
publicationDate 2016-12-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber US-2016348180-A1
titleOfInvention Methods for assessing cisplatin resistance, disease progression, and treatment efficacy in ovarian cancer
abstract The invention provides methods for predicting whether an ovarian cancer patient's tumor will be resistant to chemotherapy. The invention also provides methods for monitoring the effectiveness of treatment, particularly a chemotherapeutic treatment, in a patient treated for ovarian cancer. The invention further provides methods for treating ovarian cancer, by reducing chemotherapeutic drug resistance in said cells. In addition, the invention provides methods of screening compounds to identify tumor cell growth inhibitors in tumor cells resistant to conventional chemotherapeutic treatment regimes.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11493519-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020232416-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022232024-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11340231-B2
priorityDate 2003-12-31-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID460612
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393686
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID36314
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6917655
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226583483
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID36462
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60961
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9860982
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5284558
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396288
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4332
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID57240296
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396287
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226607444
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396360
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396057
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226399393
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID227122952
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226397441
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226399392
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID227122951
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID443118
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2907
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID20054918

Total number of triples: 57.